Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)

BACKGROUND: The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5 years suggested no improvement in disease-free survival with FEC-D....

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, E., Cameron, D., Waters, R., Barrett-Lee, P., Ellis, P., Russell, S., Bliss, J.M., Hopwood, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166460/
https://www.ncbi.nlm.nih.gov/pubmed/25065293
http://dx.doi.org/10.1016/j.ejca.2014.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166460/
https://www.ncbi.nlm.nih.gov/pubmed/25065293
http://dx.doi.org/10.1016/j.ejca.2014.06.007

Ejemplares similares